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Bioanalytical methods are widely used for quantitative estimation of drugs and their metabolites in
physiological matrices. These methods could be applied to studies in areas of human clinical pharma-
cology and toxicology. The major bioanalytical services are method development, method validation and
sample analysis (method application). Various methods such as GC, LC–MS/MS, HPLC, HPTLC, micellar
electrokinetic chromatography, and UFLC have been used in laboratories for the qualitative and quan-
titative analysis of carbamazepine in biological samples throughout all phases of clinical research and
quality control. The article incorporates various reported methods developed to help analysts in choosing
crucial parameters for new method development of carbamazepine and its derivatives and also enu-
merates metabolites, and impurities reported so far.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
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One of the major challenges faced by the pharmaceutical in-
dustry today is ﬁnding new ways to increase productivity, de-
crease costs whilst still ultimately developing new therapies thaton and hosting by Elsevier B.V. All
University.
pras_anna@yahoo.comenhance human health. Bioanalytical methods are widely used for
quantitative estimation of drugs and their metabolites in physio-
logical matrices, and could be applied to studies in area of human
clinical pharmacology and nonhuman pharmacology/toxicology
that involves evaluation and interpretation of bioequivalence,
pharmacokinetic, and toxicokinetic studies. The major bioanaly-
tical services include method development, method validation and
sample analysis (method application).
Chromatographic methods such as gas chromatography (GC),rights reserved. This is an open access article under the CC BY-NC-ND license
P.A. Datar / Journal of Pharmaceutical Analysis 5 (2015) 213–222214liquid chromatography–mass spectrometry (LC–MS), and high
performance liquid chromatography (HPLC) are commonly used in
laboratories for the qualitative and quantitative analysis of drug
substances and biological samples throughout all the phases of
method development of a drug in research and quality control.
Further, method validation is carried out to ensure that the
method developed was accurate, speciﬁc, reproducible and rugged
over the speciﬁed range in which an analyte is analyzed. The
present review covers the wide range of chromatographic tech-
niques used in determination of carbamazepine (CBZ) and its
congeners. It also incorporates records for simultaneous estima-
tions performed using analytical techniques for CBZ or its con-
geners with other drug members, impurities and metabolites.
CBZ is an anticonvulsant and mood-stabilizing drug used pri-
marily in the treatment of epilepsy and bipolar disorder, as well as
trigeminal neuralgia in old age patients. CBZ is indicated for the
treatment of partial seizures with simple or complex symptoma-
tology (psychomotor, temporal lobe) and genaralized tonic-clonic
seizures (grand mal). CBZ is also used as a diuretic and antic-
holinergic. CBZ is a ﬁrst-choice anticonvulsant because of its re-
latively low psychological toxicity and the rarity of serious adverse
effects. CBZ was discovered in 1953 by chemist Walter Schindler at
J.R. Geigy AG in Basel, Switzerland. The drug was then synthesized
in 1960 by chemist Schindler. Later, its anti-epileptic properties
were discovered. In 1971, Drs. Takezaki and Hanaoka ﬁrst used CBZ
to control mania in patients' refractory to antipsychotics. CBZ was
ﬁrst marketed as a drug to treat trigeminal neuralgia in 1962. It
has been used as an anticonvulsant and antiepileptic in the UK
since 1965, and has been approved in the US since 1974. It is of-
ﬁcial in most of the pharmacopoeias. It is the drug of choice for
many combination therapies and used in treatment of geriatric
patients with multiple disease states. Method development for
such combination product formulations is still a challenge.2. Mechanism of action
CBZ acts postsynaptically by limiting the ability of neurons to
sustain high frequency repetitive ﬁring of action potentials
through enhancement of sodium channel inactivation. In addition
to altering neuronal excitability, it may act presynaptically to block
the release of neurotransmitter by blocking the presynaptic so-
dium channels and the ﬁring of action potentials, which in turn
decreases synaptic transmission. Pain relief is believed to be as-
sociated with blockade of synaptic transmission in the trigeminal















Fig. 1. Metabolites ofpotentiation of synaptic transmission in the spinal cord [1].
CBZ has a narrow therapeutic index and the relationship be-
tween dose and plasma concentrations of CBZ may be un-
predictable because of differences in genetics, age, gender, ab-
sorption, autoinduction and disease state between individuals.
Also, the presence of numerous clinically signiﬁcant drug inter-
actions supports the need of using therapeutic monitoring of CBZ
as an essential tool in designing a safe and effective therapeutic
regimen for patients with epilepsy [2,3].
CBZ (5H-dibenzo[b, f]azepine-5-carboxamide) is insoluble in
water, soluble in alcohol, acetonitrile and acetone. CBZ is available
in market with the brand names Carbamazepen, Carbatrol, Car-
bazepine, Carbelan and Epitol. Although CBZ is poorly soluble in
aqueous media, it has a high oral bioavailability in humans [4].
Metabolism occurs primarily in the liver via the cytochrome
P-450 oxidase system, producing carbamazepine-l0, 11-epoxide
(CBZ-EP) which is as active and may reach a level up to half that of
CBZ. This is almost entirely converted to carbamazepine-trans-10,
11-dihydrodiol (CBZ–Di OH) by epoxide hydrolase before excretion
in the urine (Fig. 1). CBZ along with its metabolite was required to
be routinely measured, since there were patients for whom high
concentrations of this metabolite could be responsible for other-
wise unexplained toxicity. These toxicities may be due to de-
gradation products, metabolites present as impurities in the for-
mulation, such impurities can be studied by forced degradation of
CBZ under acid, base, oxidation, heat and photolytic conditions.
Degradation was observed in CBZ samples under stress conditions
like acid hydrolysis, photolysis and thermal exposure. Mild de-
gradation was observed for alkaline hydrolysis and exposure to
oxidation by hydrogen peroxide [5,6].
Identiﬁcation and determination of unknown organic im-
purities is the key to the production of high quality drug sub-
stances. ICH guidelines indicate that impurities at or above 0.1% in
the drug substance require identiﬁcation [7]. Fig. 2 gives the list of
pharmacopoeial impurities in CBZ reported in EP and BP.
Various chromatographic methods such as GC, LC, LC–MS,
HPLC, high performance thin layer chromatography (HPTLC), ultra-
force liquid chromatography (UFLC) and micellar electrokinetic
chromatography (MEKC) were used in laboratories for the quali-
tative and quantitative analysis of CBZ.3. GC
GC is a common type of chromatography used in analytical






































Fig. 2. Pharmacopoeial impurities in carbamazepine.
P.A. Datar / Journal of Pharmaceutical Analysis 5 (2015) 213–222 215vaporized without decomposition. In GC, the mobile phase is a
carrier gas, usually an inert gas such as helium or an unreactive gas
such as nitrogen. The stationary phase is a microscopic layer of
liquid or polymer on an inert solid support, inside a piece of glass
or metal tubing called a column. The gaseous compounds being
analyzed interact with the walls of the column, which is coated
with a stationary phase. This causes each compound to elute at a
different time, known as the retention time of the compound [8–
12].
A simple, accurate and sensitive microextraction by packed
sorbent-gas chromatography–mass spectrometry method has
been developed by Rani et al. [13] for the simultaneous quantiﬁ-
cation of four antiepileptic drugs such as oxcarbazepine (OXCBZ),
CBZ, phenytoin, and alprazolam in human plasma and urine as a
tool for drug monitoring. Caffeine was used as internal standards
for the electron ionization mode. An original pretreatment pro-
cedure on biological samples, based on microextraction in packed
syringe using C18 as packing material gave high extraction yields in
the range of 69.92%–99.38% with satisfactory precision of
RSDo4.7% and good selectivity. Linearity was found in the range
of 0.1–500 ng/mL for these drugs with limits of detection (LOD)
between 0.0018 and 0.0036 ng/mL. In validation, the method was
successfully applied to some plasma samples from patients un-
dergoing therapy with one or more of these drugs. The present
method was applied for the analysis of these drugs in the real
urine and plasma samples of the epileptic patients.
Speed et al. [14] described a rapid method for simultaneously
determining the anticonvulsant drugs such as CBZ, phenobarbi-
tone, phenytoin, primidone and valproic acid. Calibration gives
reliable quantitation from therapeutic to higher concentrations.
Deuterated internal standards were extracted using Bond ElutCertify columns. Butyl derivatives were formed using n-iodobu-
tane under mild conditions and were extracted into ethyl acetate.
Recoveries were found to be greater than 50%. Sample preparation
time was less than 2 h, and the GC run time was less than 20 min
per injection. At least two ion pairs formed by electron impact
ionization were monitored for each drug. Intraday CV's was less
than 6.28% and interday CV's less than 14.1%. Linearity was ob-
served from subtherapeutic to high fatal levels for all drugs.4. LC
A number of LC methods with UV detection for the determi-
nation of CBZ and its metabolite in drug products and human
plasma have been described [15–17]. LC–MS methods have also
been reported for the determination of CBZ [18,19] and its meta-
bolites [20,21] in biological ﬂuids. Although they provide im-
proved sensitivity and speciﬁcity compared with other analytical
methods, MS procedures were more expensive than HPLC-UV.
Breton et al. [20] described a speciﬁc and sensitive liquid chro-
matography–electrospray ionization mass spectrometry method for
the simultaneous determination of CBZ, OXCBZ and eight of their
metabolites such as CBZ-10,11-epoxide (CBZ-EP), 10,11-dihydro-
10,11-trans-dihydroxy-carbamazepine (DiOH-CBZ), 10-hydroxy-
10,11-dihydro-CBZ (10-OH-CBZ), 2-hydroxycarbamazepine (2-OH-
CBZ), 3-hydroxycarbamazepine (3-OH-CBZ), iminostilbene (IM),
acridone (AO) and acridine (AI) in human plasma. Separation of the
analytes was achieved within 50 min using a Zorbax eclipse XD8 C8
analytical column. The mobile phase consisted of a mixture of
acetonitrile–formate buffer (2 mM, pH 3). Detection was performed
using a quadrupole mass spectrometer ﬁtted with an electrospray
ion source. Mass spectrometric data were acquired in single ion
recording mode at m/z 237 for CBZ, m/z 180 for CBZ-EP and AI, m/z
236 for OXCBZ, m/z 237 for 10-OH-CBZ, m/z 253 for 2-OH-CBZ,
3-OH-CBZ and DiOH-CBZ, m/z 196 for AO and m/z 194 for IM. The
extraction recovery averaged 90% for CBZ, 80% for OXCBZ and was
80%–105% for the metabolites. The lower limit of quantitation
(LLOQ) was 0.5 mg/L for CBZ, 0.4 mg/L for OXCBZ and ranged from
0.02 to 0.3 mg/L for the metabolites. Precision ranged from 2% to
13% and accuracy was between 86% and 112%.
Sener et al. [21] described analytical method for determination
of CBZ and its metabolite CBZ-EP using ESI–LC–MS (ion trap). The
compounds were separated on a C18 (150 mm 2.1 mm i.d., 3 mm
particles) column and were isocratically eluted in the mobile
phase consisting of water–acetonitrile–acetic acid (74.5:25:0.5,
v/v/v) using the ﬂow rate of 0.4 mL/min. OXCBZ was used as an
internal standard. The retention time for CBZ-EP, OXCBZ and CBZ
was 5.6, 6.8, and 12.8 min, respectively. Signals of the compounds
were monitored under the multi-reaction monitoring mode of
ESI–LC–MS (ion trap) for the quantiﬁcation. Selected ions of CBZ-
EP, OXCBZ and CBZ in the multi-reaction monitoring were m/z
2534210, m/z 2534180 and m/z 2374194. The method was
validated over the concentration range of 5.0–500.0 ng/mL.
Liquid chromatography/tandem mass spectrometry (LC–MS/
MS) is a hyphenated technique, combining the separation power of
HPLC with the detection power of mass spectrometry. LC–MS/MS
is highly selective and sensitive and includes high speed, low de-
tection limits, the ability to generate structural information, the
requirement of minimal sample treatment and the possibility to
cover a wide range of analytes that differ in their polarities.
LC–MS/MS and liquid chromatography with quadrupole-time of
ﬂight mass spectrometry (LC-Q-TOF MS) have recently been re-
ported for the determination of CBZ in aquatic environment [22].
A sensitive method for the determination of CBZ and CBZ-EP in
plasma was described by Van Rooyen et al. [23] using high-per-






Fig. 3. Structure of impurity tetrabenzo[b,f,b'f']azepino[4′,5′:4,5]thieno[2,3-d]aze-
pine-3,9-dicarboxamide.
P.A. Datar / Journal of Pharmaceutical Analysis 5 (2015) 213–222216spectrometry. Samples were separated on a Phenomenex Luna C18
150 mm2 mm, 5 mm column with a mobile phase consisting of
acetonitrile, methanol and formic acid (0.1%) (10:70:20, v/v/v).
Detection was performed by a Micromass Quattro Ultima mass
spectrometer in the multi-reaction monitoring mode using elec-
trospray ionization (ESIþ). The transition of the protonated mo-
lecular ion was found for CBZ at m/z 237.05 and CBZ-EP at m/z
253.09 to the predominant ions of m/z 194.09 and 180.04, re-
spectively. The mean recovery was 95% for CBZ and 101% for CBZ-
EP, with a lower limit of quantiﬁcation of 0.722 ng/mL for CBZ and
5.15 ng/mL for CBZ-EP.
LC–MS studies were performed to get molecular weight, es-
tablish mass fragmentation proﬁle and identify an unknown im-
purity in CBZ active pharmaceutical ingredient. Unknown impurity
was isolated using semi-preparative HPLC. An LC–MS compatible
reverse phase isocratic method was developed and tandem mass
spectrometry was performed using electrospray ionization source
and ion trap mass analyzer [24].
A rapid tandem mass spectrometric (MS/MS) method for the
quantiﬁcation of OXCBZ in human plasma using imipramine as an
internal standard has been developed and validated [25]. Plackett–
Burman design was applied for screening of chromatographic and
mass spectrometric factors. Factorial design was applied for opti-
mization of essential factors for the robustness study such as the
percentage of acetonitrile in mobile phase, ﬂow rate, autosampler
temperature, column oven temperature, declustering potential,
collision energy and exit potential. Chromatographic separation
was achieved isocratically on C18 reversed phase column within
3.0 min using a mobile phase of acetonitrile–10 mM ammonium
formate (90:10, v/v) at a ﬂow rate of 0.3 mL/min. Quantitation was
achieved by using multiple reaction monitoring (MRM) scan at
MRM transitions m/z 2534208 and m/z 281486 for OXCBZ and
imipramine, respectively. Calibration curves were linear over the
concentration range of 0.2–16 mg/mL (r40.999) with a limit of
quantiﬁcation of 0.2 mg/mL. Analytical recoveries of OXCBZ from
spiked human plasma were in the range of 74.9%–76.3%. Stability
studies showed that OXCBZ was stable for at least 3 months in
both actual and spiked human plasma samples when frozen at or
below 20 °C. The mean (SD) recoveries for actual samples (from
the ﬁrst determination) were 104%78% (n¼6) for OXCBZ. OXCBZ
was stable for at least 6 h at room temperature in spiked human
plasma samples; the mean recoveries from the nominal con-
centration were 95%–106%. OXCBZ in working solutions was found
to be stable for at least two weeks at 2–8 °C. The mean recoveries
(n¼3) from the nominal concentrations were 88%–101% for
OXCBZ, at 8.0 mg/mL and OXCBZ was also found to be stable in
working solutions for at least 6 h at room temperature in darkness.
The mean recoveries (n¼3) from the nominal concentration of
OXCBZ at LQC and HQC concentrations were at 0.2 and 16.0 mg/mL
respectively. Extracts at concentrations of LQC and HQC were
found to be stable on the autosampler at 10 °C for at least 12 h.
Arithmetic mean recovery values after three freeze–thaw cycles
were between 95% and 105% of the nominal value for LQC and
HQC, respectively.
The MS and MS/MS studies [24] were performed on Thermo
LCQAdvantage (Thermo Electron, San Jose, CA, USA) using elec-
trospray ionization source and ion trap mass spectrometer. The
source voltage was maintained at 3.0 kV and the capillary tem-
perature was at 250 °C. Nitrogen was used as both sheath and
auxiliary gas. The mass to charge ratio was scanned across the
range of m/z 50–1000. MS/MS studies were carried out by keeping
normalized collision energy at 25% and an isolation width of
1 amu. The HPLC consisted of Waters alliance 2690 separation
module equipped with a 2487 UV detector and a column oven. A
C18 column (Inertsil ODS-3, 250 mm4.6 mm i.d., 5 mm particles)
was used for chromatographic separation. The mobile phaseconsisted of a mixture of water–methanol–triﬂuoroacetic acid
(30:70:0.05, v/v/v). The ﬂow rate was maintained at 1.0 mL/min.
Mass spectral data showed protonated molecular ion peaks at m/z
237, m/z 196 and m/z 501 for CBZ, impurity-A and impurity-B,
respectively. On the basis of RRT and mass spectral data, impurity-
A having molecular ion peak at m/z 196 was identiﬁed as imino-
dibenzyl. The mass spectral data obtained for impurity-B at RT
95.8 min did not match with any of the known impurities. Im-
purity-B was inferred to be unknown based on the HPLC and
LC–MS spectral data. The proposed structure was further con-
ﬁrmed by using NMR, FT-IR and elemental analyzer studies and
the molecular formula of unknown impurity was deduced as
C30H20N4O2S and the corresponding structure was characterized
as tetrabenzo[b,f,b'f']azepino[4′,5′:4,5]thieno[2,3-d]azepine-3,9-
dicarboxamide (Fig. 3).
LC–MS method has been proven to be powerful for the char-
acterization of the metabolites of CBZ in patient urine [26]. CBZ-EP
(9.6–15.0 mg/mL), trans-10, 11-dihydrodiol-CBZ (273.0–400.0 mg/mL)
and CBZ (2.4–3.8 mg/mL) were measured in human urine by HPLC.
An LC–MS/MS method has been developed for the simulta-
neous determination of CBZ and its main metabolite CBZ-EP in rat
plasma [27]. The method consisted of a liquid–liquid extraction
procedure and electrospray LC–MS/MS analysis for the determi-
nation of CBZ and CBZ-EP in rat plasma with an isotope labeled
internal standard. The LC–MS/MS system was equipped with a
BASi PM-80 pump (BASi, West Lafayette, IN, USA) coupled to a
Finnigan LCQ Deca ion trap mass spectrometer (ThermoQuest, San
Jose, CA, USA) equipped with an ESI source. The chromatographic
separation was achieved within 5 min using a C8
(150 mm2.1 mm, 5 mm) column (Supelco, Bellefonte, PA, USA)
with a mobile phase composed of water/acetonitrile/acetic acid
(69.5:30:0.5, v/v/v) at a ﬂow rate of 0.4 mL/min. Samples were
injected by an autosampler (Sample Sentinel, BASi), which was set
at 10 °C and ﬁtted with a 20 mL loop. The mass spectrometer was
operated in ESI positive ion mode. Nitrogen gas was used as both
the sheath and auxiliary gas at a pressure of 80 and 20 units, re-
spectively. The spray and capillary voltage were set at 5.0 kV and
22 V, respectively. The capillary temperature was set at 275 °C.
D10-carbamazepine was used as the internal standard for all
compounds. Analytes were determined by electrospray ionization
tandemmass spectrometry in the positive ion mode using selected
reaction monitoring (SRM). CBZ was monitored by scanning m/z
2374194, CBZ-EP by m/z 2534210 and d10-carbamazepine by m/
z 2474204. The LLOQ was 5 ng/mL for each analyte, based on
0.1 mL aliquots of rat plasma. The extraction recovery of analytes
from rat plasma was over 87%. Intra-day and inter-day assay
coefﬁcients of variations were in the range of 2.6%–9.5% and
4.0%–9.6%, respectively. Linearity was observed over the range of
5–2000 ng/mL. This method was used for pharmacokinetic studies
of CBZ and CBZ-EP in response to two different blood sampling
P.A. Datar / Journal of Pharmaceutical Analysis 5 (2015) 213–222 217techniques (i.e. manual sampling via a jugular catheter versus
automated sampling by using Culex automated blood sampler) in
the rat. Several differences between the two sampling techniques
suggest that the method of blood collection affects the evaluation
of pharmacokinetic data. Automated blood sampling offers several
advantages, such as an easy and accurate blood drawing and low
animal stress.
A simple, accurate, and sensitive LC–MS/MS method has been
developed by Kima et al. [28] for the simultaneous quantiﬁcation
of CBZ in human plasma as a rapid tool for drug monitoring using
d10-phenytoin and d6-valproic acid as internal standards for the
positive- and negative-ionization modes, respectively. Plasma
samples were precipitated by the addition of acetonitrile and su-
pernatants were analyzed on a C18 reverse-phase column using an
isocratic elution. The mobile phase consisted of 5 mM ammonium
formate buffer (pH 7.8) and 90% acetonitrile containing 5 mM
ammonium formate (60:40, v/v). The ﬂow rate was 0.2 mL/min.
The HPLC system was coupled to a Qtrap 4000 triple–quadrupole
mass spectrometer (AB Sciex, Foster City, CA, USA) equipped with
an electrospray ionization (ESI) source. Detection was carried out
in SRM mode. The calibration curves were linear over a 50-fold
concentration range, with correlation coefﬁcients (r2) greater than
0.997 for all antiepileptic drugs. The intra- and inter-day precision
was less than 12%, and the accuracy was between 85.9% and
114.5%. The intra-day coefﬁcients of variation were between 4.0%
and 8.2%, and accuracy ranged from 85.2% to 105%. The inter-day
coefﬁcients of variation were between 6.7% and 12.0%, and the
accuracy was between 90.6% and 107%. The absolute recovery of
antiepileptic drugs was between 94.6% and 105%. Stability was
assessed by analyzing three replicate plasma samples after three
different manipulations: (i) short-term storage (6 h at room tem-
perature); (ii) three freeze–thaw cycles and (iii) post-treatment
storage (24 h at room temperature). The concentrations obtained
were compared with the nominal values of the QC samples. The
stabilities of the stock solutions of analytes after three weeks at
4 °C and after 4 months at 80 °C were evaluated by comparison
with freshly prepared solutions of the same concentrations.
Loureiro et al. [29] developed and validated a sensitive and spe-
ciﬁc enantioselective LC–MS/MS method, for the simultaneous
quantiﬁcation of eslicarbazepine acetate (ESL), eslicarbazepine (S-
Lic), OXCBZ and R-licarbazepine (R-Lic) in human plasma. Analytes
were extracted from human plasma using solid phase extraction, and
the chromatographic separation was achieved using a mobile phase
of 80% n-hexane and 20% ethanol/isopropyl alcohol (66.7/33.3, v/v). A
Daicel CHIRALCEL OD-H column (5 μm, 50 mm4.6 mm) was used
with a ﬂow rate of 0.8 mL/min, and a run time of 8 min. ESL, S-Lic,
R-Lic, OXCBZ and the internal standard, 10,11-dihydrocarbamazepine,
were quantiﬁed by positive ion electrospray ionization mass spec-
trometry. This method was fully validated, demonstrating acceptable
accuracy, precision, linearity, and speciﬁcity in accordance with FDA
regulations for the validation of bioanalytical methods. Linearity was
proven over the range of 50.0–1000.0 ng/mL for ESL and OXCBZ and
over the range of 50.0–25,000.0 ng/mL for S-Lic and R-Lic. The intra-
and inter-day coefﬁcient of variation in plasma was less than 9.7% for
ESL, 6.0% for OXCBZ, 7.7% for S-Lic and 12.6% for R-Lic. The accuracy
was between 98.7% and 107.2% for all the compounds quantiﬁed. The
LLOQ was 50.0 ng/mL for ESL, S-Lic, OXCBZ and R-Lic in human
plasma. The short-term stability in plasma, freeze–thaw stability in
plasma, frozen long-term stability in plasma, autosampler stability
and stock solution stability all met acceptance criteria.
A quantitative method was described for solid-phase extraction
(SPE) followed by LC–MS/MS for the simultaneous analysis of CBZ and
its ﬁve metabolites, 10,11-dihydro-10,11-epoxycarbamazepine, 10,11-
dihydro-10,11-dihydroxycarbamazepine, 2-hydroxycarbamazepine, 3-
hydroxycarbamazepine and 10,11-dihydro-10-hydroxycarbamazepine
[30]. An SPE procedure was used to concentrate target compoundsfrom aqueous samples collected from sewage treatment plant (STP)
wastewater and surface water. Extracts were analyzed using electro-
spray LC–MS/MS with time-scheduled SRM. The recoveries of the
analytes were 83.6%–102.2% from untreated sewage (inﬂuent), 90.6%–
103.5% from treated sewage (efﬂuent) and 95.7%–102.9% from surface
water samples. The instrumental detection limits were 0.8–4.8 pg for
the analytes. Matrix effects were investigated for the analytes in HPLC-
grade water, surface water, and STP inﬂuent and efﬂuent. Ion sup-
pressionwas increased for analytes in the order of surface water to STP
efﬂuent to STP inﬂuent, but no ion suppression was observed for
analytes in HPLC-grade water. The developed method was validated
by analysis of environmental aqueous samples: STP inﬂuent and ef-
ﬂuent and surface water. CBZ and all ﬁve metabolites were detected in
STP inﬂuent and efﬂuent samples. Only CBZ and 10,11-dihydro-10,11-
dihydroxycarbamazepine were detected in the surface water sample.
Notably, 10,11-dihydro-10,11-dihydroxycarbamazepine was detected at
the concentration approximately three times higher than that of the
parent drug, CBZ, in all of the aqueous samples.5. HPLC
HPLC is a chromatographic technique used to separate the
components in a mixture, to identify each component, and to
quantify each component. In general, the method involves a liquid
sample being passed over a solid adsorbent material packed into a
column using a ﬂow of liquid solvent. Each analyte in the sample
interacts slightly differently with the adsorbent material, thus re-
tarding the ﬂow of the analytes. If the interaction is weak, the
analytes ﬂow off the column in a short amount of time and if the
interaction is strong, then the elution time is long.
HPLC methods for the determination of CBZ related impurities
were reported in USP, EP, BP and IP. A number of HPLC methods for
simultaneous determination of CBZ and its metabolites in plasma
have been published, using pretreatment techniques such as liquid–
liquid extraction [31–45], SPE [46–52], deproteinization [53,54], stir
bar-sorptive extraction [55], ﬂuorescence polarization immunoassay
[56,57], chemiluminescence [58], spectrophotometry [59], spectro-
ﬂuorimetry method [60], FT-Raman spectroscopy [61], and planar
chromatography [62]. However, with some of these techniques, the
obtained extraction yields were not satisfactory: most of them were
time-consuming, and some required expensive instrument, render-
ing them not appropriate for routine drug monitoring [63].
In bioanalytcal methods, the determination of CBZ in biological
ﬂuids usually involves an isolation procedure prior to the chro-
matographic step. The most frequently used procedures are li-
quid–liquid extraction [64–69], protein precipitation [70,71] and
off-line SPE with disposable extraction disk cartridge [72] or Bond-
Elut cartridge [73]. These methods are labor intensive and time
consuming and they also require a large volume of sample, as well
as addition of an internal standard. Therefore, it is advantageous to
inject the sample directly into a liquid chromatographic system
without an off-line procedure. Different approaches have been
used for direct-injection determination of CBZ in biological ﬂuids
by HPLC. The methods include micellar chromatography [74,75],
restricted access media columns such as Biotrap amine and acid
precolumn [76,77] and column switching techniques employing
conventional reversed-phase precolumn [78].
5.1. API and metabolites
HPLC was performed by using reversed-phase 1.5 mm mono-
sized non-porous silicon dioxide microspheres column instead of
regular columns containing spherical porous C18 material and was
studied to achieve decrease in run time and speciﬁcity [41]. De-
termination of CBZ and its active metabolite, CBZ-EP, in human
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these columns. The sample was prepared in autosampler vials by
protein precipitation with acetonitrile, followed by a quick cen-
trifugation. Without any change to a conventional HPLC system,
CBZ and CBZ-EP were well separated in less than 2.5 min using a
Kovasil MS C14 column. No interference was observed with en-
dogenous compounds and with nine antiepileptic drugs com-
monly prescribed as co-medication, and their metabolites. Due to
the very low speciﬁc surface area of the packing, the required
organic modiﬁer volume per chromatographic run was decreased
by a factor of 25. The developed method was found to be well
suited for the determination of CBZ and CBZ-EP in clinical trials.
A simple, rapid, sensitive, and reproducible HPLC method for
simultaneous determination of CBZ and two metabolites, carba-
mazepine-diol and CBZ-EP, in human plasma has been developed
and validated by Matar et al. [79]. The procedure involved ex-
traction of the antiepileptic drugs such as ethosuximide, primi-
done, lamotrigine, phenobarbital, phenytoin, and CBZ and two
metabolites such as carbamazepine-diol and CBZ-EP from human
plasma (100 mL) with ether using 9-hydroxymethyl-10-carbamyl
acridan as an internal standard. The extract was evaporated and
reconstituted with mobile phase and then injected onto the
chromatograph. The drugs and the internal standard were eluted
from a Supelcosil LC-18 stainless steel column at ambient tem-
perature with a mobile phase consisting of a 0.01 M phosphate
buffer/methanol/acetonitrile (65:18:17, v/v/v) adjusted to a pH of
7.5 with phosphoric acid and a ﬂow rate of 1 mL/min. The efﬂuent
was monitored at 220 nm. Quantitation was achieved by using
peak area ratio of each drug to the internal standard. The in-
traassay and interassay coefﬁcients of variation (CV) ranged from
2.43% to 6.25% and from 3.02% to 5.85%, respectively. The absolute
extraction and relative analytical recoveries for the drugs ranged
from 70.7% to 104.4% and from 88.3% to 106.1%, respectively. Sta-
bility tests showed that the drugs were stable in plasma for at least
4 weeks when stored at 20 °C. The method was applied clinically
for monitoring the antiepileptic drugs in epileptic patients.
A method by using on-line coupling of SPE has been developed
based on a restricted-access support with high performance re-
verse phase chromatography for the analysis of CBZ and CBZ-EP in
human plasma samples [80]. The liquid chromatographic system
consisted of a Waters Alliance HT HPLC system (Milford, MA, USA)
connected to a Waters 996 photodiode array (PDA) detector. For
the column-switching purposes, a column switching six-port valve
(Waters) controlled by the work station and an additional Knauer
64 pump (Berlin, Germany) to deliver the analysis eluent were
used. The following columns used in this study are ODS-Hypersil,
(125 mm4 mm i.d., 5 mm) (Hewlett-Packard) as analytical col-
umn and a LiChrocart 25-4 LiChrospher RP-18 ADS (25 mm4 mm
i.d., 25 mm particle diameter; Merck, Darmstadt, Germany) as ex-
traction precolumn. A precolumn packed with 25 mm C18 alkyl-diol-
silica support was used for plasma injection using column-switch-
ing technique. The analyte was enriched on the precolumn by a
5 mm phosphate buffer (pH 7) with 2% of methanol solution at a
ﬂow-rate of 0.8 mL/min, while proteins and endogenous hydro-
philic substances in plasma were washed off to waste. The enriched
analytes were then back-ﬂushed onto the analytical C18 column,
separated by a mixture of 10 mM phosphate buffer (pH 7) and
acetonitrile solution (70:30, v/v) at a ﬂow-rate of 1.0 mL/min and
detected by the ultraviolet absorbance set at 212 and 285 nm and
without transfer loss. Linear calibration graphs were obtained for
sample injection volume of 50 mL containing 0.2–4.0 mg/mL of CBZ
and 0.1–5.0 mg/mL of CBZ-EP, and 20 mL containing 5.0–20.0 mg/mL
of CBZ; in either case the r-value was40.9963. Recoveries from
spiked plasma samples were quantitative for both the analytes and
the coefﬁcient of variation was below 3.83%. The lowest sample
concentration that can be quantiﬁed with acceptable accuracy andprecision was 0.2 mg/mL of CBZ and 0.1 mg/mL of CBZ-EP when a
sample volume of 50 mL was injected. Concentrations of 0.08 and
0.05 mg/mL of CBZ and CBZ-EP were considered the limit of detec-
tion for a signal-to-noise ratio of 3. The developed column-
switching method was successfully applied to the determination of
CBZ and CBZ-EP in plasma samples.
Ribarska et al. [81] optimized and validated a simple and reli-
able SPE method followed by a reversed-phase (RP)-HPLC for the
simultaneous determination of plasma levels of CBZ and CBZ-EP, in
order to assure the implementation of the method for therapeutic
monitoring. Nitrazapam was used as an internal standard. The
extraction of the analytes from the plasma samples was performed
by means of an SPE procedure. Separation was performed on a
reversed-phase column Zorbax Extend C18 (150 mm4.6 mm,
5 μm) using isocratic elution with acetonitrile and water (35:65, v/
v) as a mobile phase, at a ﬂow rate of 1 mL/min. The temperature
was 30 °C, the volume of injection was 20 μL, and UV detection
was set at 220 nm. Within-run assay precision ranged from 0.6% to
1.2% for CBZ and from 0.7% to 2.0% for CBZ-EP, while within-run
assay accuracy ranged from 98.4% to 101.3% and 97.0% to 100.6% for
CBZ and CBZ-EP, respectively. The extraction yields were in the
range of 98.5%–99.6% for CBZ and 99.1%–99.7% for CBZ-EP, while
the recovery value for nitrazapam was 98.9%. The extraction yield
values were more than 98% for all the analytes, measured at four
concentration levels of the linear concentration range. The method
has shown excellent selectivity, sensitivity, linearity, precision and
accuracy. Stability studies indicate that stock solutions and plasma
samples were stabile under different storage conditions at least
during the observed period. Stability tests were performed on
three replicates of low and high QC samples after 24 h at room
temperature (short term stability), after three freeze–thaw cycles,
autosampler stability for 12 h, and after 90 days on samples stored
at 20 °C (long term stability). Stability tests were also performed
on stock solutions of analytes after 24 h at room temperature and
after 3 months at 2–8 °C. The method was successfully applied for
determination of CBZ and CBZ-EP in plasma of epileptic patients
treated with CBZ as monotherapy and in polytherapy.
SPE-HPLC method has been developed and validated for rapid
analysis of CBZ and its two metabolites, CBZ-EP and carbamaze-
pine trans-diol, in human plasma [82]. The analysis was performed
using C18 Bakerbond-BDC analytical column (250 mm4.6 mm i.
d., 5 μm). The optimal conditions for the separation were estab-
lished with the mobile phase acetonitrile–10 mM phosphate buf-
fer, pH 7.0 (30:70, v/v) at the ﬂow rate of 1.5 mL/min, temperature
35 °C, and UV detection at 210 nm. Total run time was about 8 min.
Phenobarbital was used as an internal standard. SPE procedure for
extraction of the analyte from plasma sample was developed using
Oasis HLB cartridges and subsequently eluate was injected into the
HPLC system for analysis. Afterwards, SPE-HPLC method was
subjected to validation. Linearity was obtained over the con-
centration range of 0.2–25 μg/mL for CBZ, CBZ-EP and carbama-
zepine trans-diol with correlation coefﬁcients higher than 0.995.
The method showed good intra-day and inter-day precision with
relative standard deviation below 7.96%, while accuracy ranged
from 92.09% to 108.5% for all the analytes. Absolute recovery was
found to be from 87.39% to 104.04%. The method was successfully
applied to analysis of plasma samples of epileptic patients in
monotherapy and polytherapy.
5.2. Combination product
A simple and sensitive method has been developed by Bhatti
et al. [83] and validated for the simultaneous determination of
PHT, CBZ and CBZ-EP in human plasma by HPLC with 10,11-dihy-
drocarbamazepine as the internal standard. Acetonitrile was ad-
ded to plasma samples containing PHT, CBZ and CBZ-EP to
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trile supernatant was transferred to a clean tube and evaporated
under nitrogen gas. The dried sample extract was reconstituted in
0.4 mL of mobile phase and injected for analysis by HPLC. Se-
paration was achieved on a Spherisorb ODS2 analytical column
with a mobile phase of acetonitrile:methanol:potassium phos-
phate buffer (18:18:70, v/v/v). Detection was at 210 nm using an
ultraviolet detector. The mean retention time of CBZ-EP, PHT and
CBZ was 5.8, 9.9 and 11.8 min, respectively. Peak height ratios were
ﬁt to a least squares linear regression algorithm with a 1/
(concentration)2 weighting. The method produces acceptable lin-
earity, precision and accuracy to a minimum concentration of
0.05 mg/mL in human plasma. The method showed no observable
matrix interferences.
Szabo et al. [84] described a method by which the heavily
deuterated 2H10 analogs of carbamazepine (2H10 CBZ) and phe-
nytoin (2H10 PHT) were chromatographically separated by HPLC
from unlabeled CBZ and PHT. All compounds were quantitated
against an internal standard, 10,11-dihydrocarbamazepine, and
measured using conventional UV detection rather than mass
spectrometry. Baseline resolution of extracted serum containing
2H10 CBZ, CBZ, 2H10 PHT, PHT and the internal standard achieved
on a heated (55 °C) 25 cm4.6 mm BioAnalytical Systems Phase II
5 μm ODS column with an isocratic mobile phase consisting of
water–acetonitrile–tetrahydrofuran (80:16:4, v/v/v) at 1.2 mL/min.
Eluting compounds were monitored at a UV wavelength of
214 nm. Calculated resolution of 2H10 CBZ from CBZ and of 2H10
PHT from PHT was 1.3. Serum standard curves were linear
(R¼0.999) over a range of 0.5–14 mg/mL for 2H10 CBZ, 0.5–
20 mg/mL for CBZ, 0.5–20 mg/mL for 2H10 PHT, and 0.5–30 mg/mL
for PHT. Within-day percent relative standard deviations (preci-
sion) were less than 6% in all cases.
An isocratic simple rapid assay has been developed and vali-
dated for the determination of CBZ in both solution form and rabbit
plasma [85] using propylparaben as an internal standard. The assay
was performed using a m-Bondapak C18 (150 mm4.6 mm) with a
mobile phase consisting of methanol and water (50:50, v/v), at a
ﬂow rate of 1 mL/min and UV detection at 285 nm. The method was
found to be speciﬁc for CBZ, and no interfering peaks were observed
with an overall analytical run time of 15 min. Inter-day and intra-
day accuracies reported as percent recovery were found to be
98.37%–100.45% and 97.53%–103.58%, respectively. Inter-day preci-
sion (reproducibility) was found to be 0.53%–2.75% RSD, while in-
tra-day precision (repeatability) was found to be 1.06%–3.7% RSD for
the samples studied. The calibration curve was found to be linear
with a correlation coefﬁcient (R2) of 0.999 over a concentration
range of 0.5–40 mg/mL. The limit of quantitation was the lowest
concentration. The method is simple and rapid and does not require
any preliminary treatment of the sample.
According to literature survey, HPLC–MS methods were pub-
lished for quantitative analysis of CBZ, its metabolites and other
medications in human plasma. The HPLC–MS techniques are not
widely used because this expensive equipment is not available in
most clinical laboratories. Prior to HPLC–MS analysis, human
plasma samples were subjected to protein precipitation, liquid–
liquid extraction, stir bar-sorptive extraction or SPE. Unfortunately,
the methods are time-consuming on account of eluate evaporation
and subsequently reconstitution in comparison with the proposed
SPE-HPLC method [86–90].
5.3. Formulation
An RP-HPLC method for the quantitative determination of CBZ
in pure forms and in pharmaceutical preparations was developed
and validated [91]. Good separation was achieved using Bondolone
C18 column (150 mm3.9 mm, 5 mm). RP-HPLC was carried outusing a mobile phase of acetonitrile-Milli-Q grade water (30:70,
v/v). The retention time was 8.2 min at a ﬂow-rate of 1 mL/min.
The injection volume was 10 mL and the peaks were detected at
220 nm. Linearity was obeyed in the range of 0.25–25 mg/mL. The
correlation coefﬁcient (r) obtained for regression equation was
found to be 0.9995. Accuracy of the method was checked for six
days at three concentration levels of 2.5, 7.5 and 15 mg/mL in six
replicates. The precision of the RP-HPLC method was demon-
strated by the relative standard derivation (RSD%) of lower than
5.88% for intra-day and 6.68% for inter-day. The limit of quantita-
tion (LOQ) value of the RP-HPLC method was determined as
0.07 mg/mL. The LOD for CBZ determination was approximately
0.05 mg/mL. Recovery was found to be 98%–101%. The stability
measurements were carried out for CBZ in solution at 4 °C and
20 °C using three sets of 2.5, 7.5 and 15 mg/mL concentrations.
Developed method was successfully applied for assay of CBZ in
pharmaceutical preparations.
Sensitive RP-HPLC and second derivative spectrophotometric
methods for determination of CBZ in tablets have been developed
[92]. In the HPLC method CBZ was separated using Phenomenex
C18 column and acetonitrile:water (75:25, v/v) as mobile phase
system. The speed of the mobile phase ﬂowing was 1 mL/min and
the detection was actualized at 285 nm. Enalapril was used as an
internal standard. For the second derivative spectrophotometric
method CBZ was determined by applying the techniques of the
peak to peak amplitude. The assay was linear in the concentration
range of 0.2–2.0 mg/mL for HPLC and 4.0–10.0 for second derivative
spectrophotometric method. The detection limits of CBZ were
0.055 and 1.25 mg/mL for HPLC and second derivative spectro-
photometric method, respectively. The recovery (%RSD) in HPLC
and derivative spectrophotometric methods was (99.2270.25)%
and (99.0570.25)%, respectively.6. HPTLC
HPTLC is an enhanced form of thin layer chromatography (TLC).
A number of enhancements can be made to the basic method of
TLC to automate the different steps, to increase the resolution
achieved, and to allow more accurate quantitative measurements
[93]. The major advantage of HPTLC is its ability to analyze several
samples simultaneously using a small quantity of mobile phase.
This reduces time and cost of analysis. In addition, it minimizes
exposure risks and signiﬁcantly reduces disposal problems of toxic
organic efﬂuents, thereby reducing possibilities of environment
pollution. HPTLC also facilitates repeated detection of chromato-
gram with the same or different parameters. The ability of HPTLC
to analyze many samples in parallel has the advantage over other
techniques in that the separation of 10 or 20 samples only takes
the same amount of time as the separation of one sample. Fur-
thermore, in case of HPTLC, there are no restrictions on the choice
of solvents and mobile phases; drug and lipophilic excipients can
be dissolved in a suitable solvent that would evaporate during
spotting on TLC plate, leaving behind analyte as a thin band.
Therefore, for such methods, extraction procedure is not always
required and could be developed for analyzing drug without any
interference from excipients [94].
A simple and rapid HPTLC method was developed and vali-
dated for quantitative determination of CBZ [95]. CBZ was chro-
matographed on silica gel 60 F254 TLC plate using ethyl acetate–
toluene–methanol (5.0: 4.0: 1.0, v/v/v) as the mobile phase. CBZ
was quantiﬁed by densitometric analysis at 285 nm. The method
was found to give compact spots for the drug (Rf¼0.4770.01).
The linear regression analysis data for the calibration plots showed
good linear relationship with r2 of 0.9995 in the concentration
range of 100–600 ng/spot. The minimum detectable amount was
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spot. Statistical analysis of the data showed that the method is
precise, accurate, reproducible and selective for the analysis of
CBZ. The method was successfully employed for the estimation of
equilibrium solubility, quantiﬁcation of CBZ as a bulk drug, in
commercially available preparation and in-house developed mu-
coadhesive microemulsion formulations and solution.
An instrumental planar chromatography method for quantita-
tive analysis of CBZ in saliva [96] and in human serum [62] was
developed. Chromatography was carried out on silica gel F254
HPTLC plates, previously washed in methanol and activated at
130 °C during 20 min. For the chromatographic development,
ethyl acetate/toluene/methanol (5:4:1, v/v/v) was used. The length
of development was 5 cm occurring in a period of 10 min. Hor-
izontal development chambers were used. The method was linear
between 0.5 and 15.0 ng/spot, with a regression coefﬁcient of
0.999. The intra-assay variation (repeatability) was between 5.1%
and 7.4%, and the inter-assay (reproducibility) was between 5.6%
and 7.4%. The detection limit was 0.18 ng, and the quantiﬁcation
limit was 0.54 ng. The method proved accurate, with a recovery
percentage of 109.8%, and it was selective for the active principle
tested. It is a good method for the quantitative determination of
CBZ in saliva.7. UFLC
UFLC offers high-speed and separation even at normal pressure
levels. By maximizing the performance of the column and the
entire system, UFLC minimizes the analysis time and offers fast LC
analysis.
A novel, accurate and precise RP-UFLC method for determina-
tion of OXCBZ has been developed and validated by Panda et al.
[97]. Separation was achieved on an Enable C18G column (250 mm
4.6 mm i.d., 5 μm) using acetonitrile: 10 mM tetra butyl am-
monium hydrogen sulfate (60:40, v/v) as mobile phase at a ﬂow
rate of 1.0 mL/min and photodiode array detection at 254 nm. The
retention time for OXCBZ was found to be 3.896 min. The run time
was 6 min. Linearity was observed in the concentration range of
0.1–250 μg/mL with a regression coefﬁcient of 0.999. The average
recovery was in the range of 100.38%–105.5%. Forced degradation
was performed by using HCl, NaOH, H2O2, thermal and UV radia-
tion. The method was used successfully for the determination of
OXCBZ in tablet dosage form.8. MEKC
MEKC is a chromatography technique used in analytical
chemistry. It is a modiﬁcation of capillary electrophoresis (CE),
where the samples are separated by differential partitioning be-
tween micelles (pseudo-stationary phase) and a surrounding
aqueous buffer solution (mobile phase). Capillary electrophoresis
has also been reported for the separation of CBZ and its metabo-
lites [98] and monitoring the concentrations of CBZ and its me-
tabolites in plasma [74,99].
MEKC is based on the addition to the buffer solution of a mi-
cellar “pseudostationary” phase, which interacts with the analytes
according to partitioning mechanisms, just like in a chromato-
graphic method. The “pseudostationary” phase is composed of a
surfactant added to the buffer solution in a concentration above its
critical micellar concentration (CMC) [100].
A reliable MEKC method for the determination of CBZ and its
two main metabolites, 10-hydroxycarbamazepine and 10,11-trans-
dihydroxy-10,11-dihydroxycarbamazepine, in human plasma has
been developed by Pucci et al. [101]. The separation anddetermination of the analytes was done using a system consisting
of 60 mM sodium dodecylsulfate in phosphate buffer (30 mM, pH
8.0), to which 20% (v/v) methanol was added. Melatonine was
used as an internal standard. Separation was carried out in an
uncoated fused-silica capillary with a separation voltage of 25 kV
and currents typically less than 40 mA. Spectrophotometric detec-
tion was at 205 nm. Isolation of OXCBZ and its metabolites from
plasma was accomplished by an SPE procedure. The mean ex-
traction yield of the analytes from plasma was higher than 94%.
The linear correlation coefﬁcients were better than 0.994 for all
analytes. LOD was 0.05 mg/mL while LOQ was 0.15 mg/mL. The in-
traday repeatability parameter for the spiked blank plasma sam-
ples was lower than 1.9% RSD and the interday intermediate pre-
cision was lower than 2.1% RSD. The results obtained by analyzing
real plasma samples from epileptic patients were found to be sa-
tisfactory in terms of precision, accuracy and detectability.
A rapid and feasible method for the analysis of CBZ and its
ﬁve metabolites (10,11-dihydro-10,11-epoxycarbamazepine, 10,11-
dihydro-10,11-dihydroxycarbamazepine, 10,11-dihydro-10-hydroxy-
carbamazepine, 2-hydroxycarbamazepine and 3-hydroxycarbama-
zepine) in human plasma has been developed by Raggi et al. [102].
Separation of the analytes was based on MEKC, in untreated fused-
silica capillary (48.5/40.0 cm length, i.d. 50 mm) with phosphate
buffer (30 mM, pH 8.0) as background electrolyte, containing
50 mM sodium dodecylsulfate and methanol (15%, v/v) as organic
modiﬁer. Clean up of human plasma samples was carried out by
means of an SPE procedure, which gave a high extraction yield for
all six carbamazepines (488%). The mean extraction yield was
96.8% for CBZ and 93.7% for the metabolites. The overall precision of
the method gave a mean RSD of about 1.8%. LOQ for all the analytes
was r0.30 mg/mL while LOD was r0.12 mg/mL.9. Overview
Bioanalytical and analytical methods require time-consuming
and laborious extraction procedures or relatively large sample
volumes (approx. 1 mL) as well as lengthy chromatographic run
times, limiting their throughput capacity and sensitivity. The
present review incorporates outline of various methods and
techniques used in quantifying CBZ and its congeners using re-
ports of analytical studies. Numbers of analytical techniques have
been used with variables such as instruments, type of stationary
phases, analytical columns and mobile phases. Numbers of com-
bination of solvent used suits the analytical methods and tools.
The review would help analytical chemists in knowing the key
solvents and their combinations for their available set of instru-
ments in the analytical laboratory. Analytical chemists can have
the knowledge of advantage of one technique over another with
the due comparisons mentioned in the published records. Apart
from single drug proﬁle records, the review also incorporates the
records of comparative studies of one or more members of the
same class of compounds. The following ofﬁcial methods for
identiﬁcation and qualitative and quantitative methods of esti-
mations are prerequisites, but for multiple components studying
the previous analytical records guide the proper selection of
methods, instruments and solvents. The effective combination of
parameters should minimize the cost of the analysis and reduce
the time required for producing a reliable analytical method. The
methods are also useful for determining parameters for in-process
evaluation during the manufacturing of API.
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